CVS Health Corporation filed its third-quarter 2026 operating results on November 4, 2026, reporting total revenues of $108.4 billion and raising its full-year 2026 guidance for GAAP diluted EPS, Adjusted EPS, and cash flow from operations.
Key Highlights
- Revenue up 5.4%: Third-quarter total revenues reached $108.4 billion, compared to $102.9 billion in the prior-year period, according to the filing.
- GAAP diluted EPS of $1.68: Compared to a loss per share of $3.13 in Q3 2025, with the prior year including a $5.7 billion goodwill impairment charge related to the Health Care Delivery reporting unit.
- Adjusted EPS of $2.09: Up from $1.60 in the prior-year quarter, primarily driven by improved adjusted operating income in the Health Care Benefits segment.
- Full-year 2026 guidance raised: GAAP diluted EPS guidance increased to at least $6.98 from a range of $6.84 to $7.04; Adjusted EPS guidance raised to at least $8.20 from a range of $7.90 to $8.10.
- Cash flow from operations guidance lifted: Full-year 2026 guidance raised to at least $15.5 billion from at least $11.5 billion; year-to-date cash flow from operations stood at $15.3 billion.
- Health Care Benefits MBR improved: The medical benefit ratio decreased to 91.3% in Q3 2026 from 92.8% in Q3 2025, the filing disclosed.
- Adjusted operating income rose 21.2%: Increases were reported across all operating segments for the three months ended September 30, 2026.
CVS Health Q3 2026 Segment Performance and Guidance Increase
CVS Health Corporation (NYSE:CVS) reported consolidated third-quarter results for the three months ended September 30, 2026, disclosing total revenues of $108,399 million, operating income of $3,566 million, and net income of $2,171 million. The operating income compared to an operating loss of $3,207 million in the prior-year period, a difference the filing attributed primarily to the absence of a $5.7 billion goodwill impairment charge recorded in Q3 2025 related to the Health Care Delivery reporting unit, combined with higher adjusted operating income.
The Health Care Benefits segment reported total revenues of $36,855 million for Q3 2026, up 2.4% compared to the prior year, driven by growth in the Government business and partially offset by the company's exit of the individual exchange business in 2026. Adjusted operating income in that segment rose to $912 million from $314 million in Q3 2025. Medical membership as of September 30, 2026 stood at 26.1 million, consistent with June 30, 2026 levels. The Health Services segment posted total revenues of $53,964 million, up 9.5% year-over-year, with pharmacy claims processed increasing 1.3% on a 30-day equivalent basis. The Pharmacy and Consumer Wellness segment reported total revenues of $35,498 million, down 2.0%, while adjusted operating income rose 10.6% to $1,635 million, with the filing citing core pharmacy strength and contributions from the company's Rite Aid asset acquisitions, which were completed during Q3 2025.
The company disclosed it is raising full-year 2026 guidance to reflect increases in the Health Care Benefits and Pharmacy and Consumer Wellness segments, while "maintaining a cautious view for the remainder of the year in light of continued elevated cost trends and the potential for macro headwinds." Projected full-year total revenues stand at at least $420.0 billion. Nine-month diluted EPS reached $6.29, compared to a loss per share of $0.93 for the same period in 2025.
What Was Disclosed
CVS Health reported Q3 2026 revenues of $108.4 billion, GAAP diluted EPS of $1.68, and Adjusted EPS of $2.09, and raised its full-year 2026 GAAP EPS, Adjusted EPS, and cash flow from operations guidance, citing segment-level improvements and the absence of a prior-year goodwill impairment.



Please wait processing your request...